{"log_id": 1933782602423058709, "direction": 0, "words_result_num": 34, "words_result": [{"probability": {"variance": 0.007683, "average": 0.975037, "min": 0.416539}, "location": {"width": 1305, "top": 155, "height": 98, "left": 185}, "words": "对那些单独使用氢氯噻嗪25mg能有效控制血压的患者,加用厄贝沙坦能使扣除安慰剂效应后的收"}, {"probability": {"variance": 0.030648, "average": 0.870731, "min": 0.4512}, "location": {"width": 500, "top": 219, "height": 61, "left": 123}, "words": "缩压/舒张厂再平均降低11.1/7.2mHg"}, {"probability": {"variance": 0.007692, "average": 0.955504, "min": 0.497173}, "location": {"width": 1300, "top": 285, "height": 98, "left": 182}, "words": "厄贝沙坦和氢氯噻嗪合用的降压效应在首剂量后就出现:1-2周内显著,最大效应在6-8周,在长期"}, {"probability": {"variance": 0.007712, "average": 0.96686, "min": 0.484288}, "location": {"width": 1362, "top": 349, "height": 100, "left": 118}, "words": "的访研究中,厄贝沙坦/氢氯噻嗪降压效应持续一年以上。尽管没有对复方进行特异的研究,但在厄贝"}, {"probability": {"variance": 0.014517, "average": 0.945834, "min": 0.471506}, "location": {"width": 683, "top": 416, "height": 73, "left": 116}, "words": "沙坦和氢氯噻嗪的治疗中均未观察到反性血玉升高"}, {"probability": {"variance": 0.010036, "average": 0.967887, "min": 0.411949}, "location": {"width": 1303, "top": 484, "height": 100, "left": 173}, "words": "有关贝沙坦和氢氯噻嗪复方对心血管发病率和死亡率的影响尚无研究:流行病学研究表明:氢氯噻"}, {"probability": {"variance": 0.007583, "average": 0.954863, "min": 0.632905}, "location": {"width": 507, "top": 551, "height": 61, "left": 112}, "words": "嗪长期治疗减少心血管发病和死亡风险"}, {"probability": {"variance": 0.010914, "average": 0.957521, "min": 0.354285}, "location": {"width": 1298, "top": 619, "height": 96, "left": 171}, "words": "不同年龄和性别的患者对本复方的反应没有差异。当厄贝沙坦和小剂量氢氯嗪(如每日12.5mg)合"}, {"probability": {"variance": 0.006635, "average": 0.96605, "min": 0.705118}, "location": {"width": 624, "top": 681, "height": 68, "left": 107}, "words": "用时,其在黑人和非黑人中的抗高血压作用接近"}, {"probability": {"variance": 0.000695, "average": 0.982328, "min": 0.920544}, "location": {"width": 194, "top": 749, "height": 45, "left": 114}, "words": "【药代动力学】"}, {"probability": {"variance": 0.000596, "average": 0.983711, "min": 0.897493}, "location": {"width": 1008, "top": 818, "height": 82, "left": 162}, "words": "合并使用厄贝沙坦和氢氯噻嗪对其中任何一种药品的药代动力学特性没有影响"}, {"probability": {"variance": 0.002898, "average": 0.975843, "min": 0.720841}, "location": {"width": 1300, "top": 884, "height": 93, "left": 160}, "words": "厄贝沙坦和氢氯噻嗪是口服有效的药物,它们发挥活性不需要生物转化:口服本品后,其绝对生物利"}, {"probability": {"variance": 0.01888, "average": 0.930742, "min": 0.365421}, "location": {"width": 1362, "top": 946, "height": 98, "left": 96}, "words": "用度在厄贝沙坦和氢氯分别为60-80%和50-80%。进食小影响本品的生物利用度。口服贝沙坦和氢"}, {"probability": {"variance": 0.009191, "average": 0.960563, "min": 0.509953}, "location": {"width": 743, "top": 1015, "height": 68, "left": 91}, "words": "氯噻嗪后血浆峰浓度时间分别为1.5-2小时和1-2.5小时"}, {"probability": {"variance": 0.006655, "average": 0.960021, "min": 0.638807}, "location": {"width": 1300, "top": 1081, "height": 98, "left": 150}, "words": "厄贝沙坦血浆蛋白的结合率大约为96%,几乎不和血细胞结合,其分布容积为53-93升。氢氯噬嗪血"}, {"probability": {"variance": 0.009407, "average": 0.951874, "min": 0.502244}, "location": {"width": 699, "top": 1147, "height": 70, "left": 89}, "words": "浆蛋白结合率为68%,表观分布容积为0.83-1.141./Kg"}, {"probability": {"variance": 0.025502, "average": 0.913771, "min": 0.352804}, "location": {"width": 1300, "top": 1218, "height": 91, "left": 148}, "words": "厄贝沙的药代动力学在10-00mng范围内呈线性和剂量相关性,当口服剂量大于600mE时,其吸收"}, {"probability": {"variance": 0.010837, "average": 0.955772, "min": 0.569686}, "location": {"width": 948, "top": 1282, "height": 75, "left": 86}, "words": "与剂量个成比例:其机理不明确,机体总清除率和肾清除率分别为157-1"}, {"probability": {"variance": 0.003292, "average": 0.904115, "min": 0.808959}, "location": {"width": 96, "top": 1328, "height": 34, "left": 1156}, "words": "和3.0-"}, {"probability": {"variance": 0.000475, "average": 0.986994, "min": 0.91826}, "location": {"width": 358, "top": 1346, "height": 54, "left": 82}, "words": "贝沙坦的终末消除半衰期为"}, {"probability": {"variance": 0, "average": 0.739671, "min": 0.739671}, "location": {"width": 29, "top": 1342, "height": 29, "left": 1412}, "words": "厄"}, {"probability": {"variance": 0.001814, "average": 0.977822, "min": 0.850175}, "location": {"width": 912, "top": 1362, "height": 80, "left": 528}, "words": "小时。按每日次的服药方法,三天内达到稳态血浆浓度。重复每日一"}, {"probability": {"variance": 0.005512, "average": 0.969271, "min": 0.662854}, "location": {"width": 1364, "top": 1412, "height": 96, "left": 77}, "words": "次给药后血浆内积蓄有限〔<20%在一项研究中观察女性高血压患者厄贝沙坦的浓度稍高。然而,其半"}, {"probability": {"variance": 0.031384, "average": 0.890567, "min": 0.38893}, "location": {"width": 1362, "top": 1479, "height": 96, "left": 75}, "words": "衰期木积蓄没有差异,女性患者不需药物剂兰调整厄贝纱的峰浓度max)和由线小积(AUC值"}, {"probability": {"variance": 0.017545, "average": 0.940735, "min": 0.508692}, "location": {"width": 1360, "top": 1545, "height": 93, "left": 73}, "words": "在老年人(≥65岁〕比年轻人(1840岁>稍高。然而终末半衰期没有明显改变。老年患者也不需要调整"}, {"probability": {"variance": 0, "average": 0.997193, "min": 0.996883}, "location": {"width": 64, "top": 1611, "height": 36, "left": 70}, "words": "剂量"}, {"probability": {"variance": 0.0159, "average": 0.936885, "min": 0.506288}, "location": {"width": 521, "top": 1680, "height": 61, "left": 128}, "words": "氢氯噻嗪的平均血浆半衰期为5-15小时"}, {"probability": {"variance": 0.01441, "average": 0.94688, "min": 0.435103}, "location": {"width": 1300, "top": 1746, "height": 96, "left": 125}, "words": "口服或静脉给予厄贝沙坦后,血液循环内80-85%的放射性米自原型的厄贝沙坦。厄贝沙坦在脏"}, {"probability": {"variance": 0.003133, "average": 0.972247, "min": 0.699034}, "location": {"width": 1360, "top": 1813, "height": 93, "left": 66}, "words": "经与葡萄糖醛酸结合和氧化而板代谢。口服主要的代谢物为葡萄糖醛酸结合型厄贝沙坦(大约为8)。体"}, {"probability": {"variance": 0.018922, "average": 0.941894, "min": 0.400361}, "location": {"width": 1362, "top": 1877, "height": 96, "left": 61}, "words": "外实验显示厄贝沙坦主要由细胞色素P450mCYP2C9氧化代谢,CYP3AA几乎没有作用厄贝沙坦及其代谢"}, {"probability": {"variance": 0.012711, "average": 0.959564, "min": 0.380974}, "location": {"width": 1362, "top": 1945, "height": 93, "left": 57}, "words": "产物胆道和肾脏排泄。口服或静脉给予“厄贝沙坦后,大约20%的放射性可在尿液中回收,其余排泄生"}, {"probability": {"variance": 0.001126, "average": 0.983246, "min": 0.838016}, "location": {"width": 1362, "top": 2009, "height": 93, "left": 54}, "words": "粪便中。不足2%的剂量以原型在尿液中排泄氢氯噻嗪不被代谢,但很快经肾排泄。至少口服剂量的"}, {"probability": {"variance": 0.009944, "average": 0.948897, "min": 0.621018}, "location": {"width": 1186, "top": 2075, "height": 84, "left": 57}, "words": "61%在24小时内以原型排泄。氧氯噻嗪可通过胎盘,但不能通过血脑屏障,可被分泌入乳汁"}, {"probability": {"variance": 0.007187, "average": 0.963905, "min": 0.506632}, "location": {"width": 1305, "top": 2142, "height": 91, "left": 112}, "words": "肾功能损害:肾功能损害的患者或那些进行血液透析的患老,厄贝沙的药代动力学参数没有明显改"}], "language": 3}